Equities

Pacific Biosciences of California Inc

Pacific Biosciences of California Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)1.95
  • Today's Change-0.468 / -19.31%
  • Shares traded2.80k
  • 1 Year change-68.81%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:09 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments6317721,044
Total Receivables, Net371924
Total Inventory575025
Prepaid expenses17107.39
Other current assets, total0.300.300.50
Total current assets7428521,101
Property, plant & equipment, net698179
Goodwill, net462410410
Intangibles, net457410411
Long term investments------
Note receivable - long term------
Other long term assets13111.17
Total assets1,7461,7672,007
LIABILITIES
Accounts payable151211
Accrued expenses554144
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.491.80--
Other current liabilities, total2420817
Total current liabilities9526372
Total long term debt893897896
Total debt893899896
Deferred income tax------
Minority interest------
Other liabilities, total5744248
Total liabilities1,0451,2041,216
SHAREHOLDERS EQUITY
Common stock0.270.230.22
Additional paid-in capital2,5402,1002,010
Retained earnings (accumulated deficit)(1839)(1532)(1218)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.22(4.77)(1.09)
Total equity701563791
Total liabilities & shareholders' equity1,7461,7672,007
Total common shares outstanding268227221
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.